explore -WSS

explore

author：focus 2025-09-04 22:14:50 - browse：4

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Why does health care cost so much? A reading guide

WSS

MultiPlan and major insurers sued for alleged medical price

Why rehabilitation engineers need to center patients in their research

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Medical bills so high, Medicare adding extra digits to claim forms

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Padmanee Sharma of MD Anderson at center of lawsuit over credit

hotspot

explore

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

MultiPlan and major insurers sued for alleged medical price

Affirmative action in medical school literally saved lives

Why CTE doesn’t keep Americans from enjoying the Super Bowl

What does generative AI mean for health care? We asked experts

Close Medicare's dangerous gaps in addiction treatment coverage

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Walensky prepares to leave CDC — and Congress — behind

What’s missing from the debate over nursing home staff minimums

entertainment

AstraZeneca stays mum on Medicare drug pricing negotiations

Medicare Advantage plans can’t deny care with AI, CMS warns

Readout LOUD: Venture capital, Gilead, and more M&A

Diversity in clinical trials starts with building trust, experts say

Problems with a popular proposal to regulate AI in health care

A protest over insulin prices is seen as a fight for life

leisure time

entertainment

knowledge

focus